Logo
x

Search

Subscribe Now

Innovent Biologics

Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis

Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis

  • October 17, 2024
The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

  • August 22, 2024
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

  • May 9, 2024
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

  • May 7, 2024
Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

  • February 20, 2024
Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tumors

Innovent Biologics Enters into a Collaboration Agreement with Xuanzhu Biopharma to Study and Supply Tyvyt with KM-501 for Solid Tu...

  • December 28, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.